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Abstract
Metastasis is the process by which cells from a primary tumor disperse and form new tumors at
distant anatomical locations. The treatment and prevention of metastatic cancer remains an extremely
challenging problem. This work introduces a novel biologically motivated objective function to the radia-
tion optimization community that takes into account metastatic risk instead of the status of the primary
tumor. In this work, we consider the problem of developing fractionated irradiation schedules that min-
imize production of metastatic cancer cells while keeping normal tissue damage below an acceptable
level. A dynamic programming framework is utilized to determine the optimal fractionation scheme. We
evaluated our approach on a breast cancer case using the heart and the lung as organs-at-risk (OAR).
For small tumor α/β values, hypo-fractionated schedules were optimal, which is consistent with standard
models. However, for relatively larger α/β values, we found the type of schedule depended on various
parameters such as the time when metastatic risk was evaluated, the α/β values of the OARs, and the
normal tissue sparing factors. Interestingly, in contrast to standard models, hypo-fractionated and semi-
hypo-fractionated schedules (large initial doses with doses tapering off with time) were suggested even
with large tumor α/β values. Numerical results indicate potential for significant reduction in metastatic
risk.
1 Introduction
Most solid tumors eventually establish colonies in distant anatomical locations; when these colonies become
clinically detectable, they are called macrometastasis. While often there is a large burden from primary
tumors, it is in fact metastatic disease that is responsible for most cancer fatalities [14, 37].
The creation of macrometastasis requires the successful completion of a sequence of difficult steps. First,
cancer cells must gain access to the general circulation system via the process of intravasation. Next, the
cells must survive in the inhospitable environment of the circulatory system. Following this, the tumor
cells must exit the circulatory system (extravasation) at a distant site and initiate micrometastsis (clinically
undetectable population of tumor cells at a distant anatomical site). Lastly, the micrometastsis must develop
the ability to successfully proliferate in the distant site and grow into clinically identifiable macrometastasis.
The completion of these steps is very difficult and only a small fraction of tumor cells are able to achieve
this [24]. However, due to the vast number of cells in most primary tumors, metastasis commonly occurs in
later stage solid tumors.
There has been significant mathematical research in the design of optimal anti-cancer therapies. This
has included studies on optimal chemotherapy, radiotherapy, and more recently targeted therapies and
immunotherapy ([31, 23, 1, 12, 8]). Since we are interested in radiotherapy we will focus on previous work in
this field. The vast majority of modeling of radiotherapy response is based on the linear-quadratic model (LQ)
which says that tissue response is governed by the parameters α and β (see e.g., [17]). Specifically, following
a single exposure to d Gray of radiation, the surviving fraction of viable cells is given by exp(−α∗d−β ∗d2).
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An important question in this field is to decide on the optimal temporal distribution of a given amount of
radiation, i.e., how to kill the most tumor cells while inflicting the least amount of normal tissue damage.
This is commonly referred to as the ‘optimal fractionation problem.’ Two possible solutions to this problem
are hyper-fractionated and hypo-fractionated schedules. In hyper-fractionated schedules, small fraction sizes
are delivered over a large number of treatment days, while in hypo-fractionated schedules, large fraction
sizes are delivered over a small number of treatment days. If we minimize primary tumor cell population
at the conclusion of treatment, it has been seen ([25] and [2]) that whether hyper or hypo-fractionation is
preferable depends on the radiation sensitivity parameters of the normal and cancerous tissue. However
we will observe in Section 4 of this manuscript that when designing optimal treatments with the goal of
minimizing metastatic production, hypo-fractionation is preferable for many parameter choices, and hyper-
fractionation is only preferable sometimes when the α/β value of the tumor is large.
There have been a substantial number of works looking at optimal fractionation. The work [35] considers
dynamic design of fractionation schedules with incomplete repair, repopulation and reoxygenation. A more
recent work [4] considers the optimization problem associated with finding fractionation schedules under
an LQ model with incomplete repair and exponential repopulation. The authors theoretically establish the
benefits of hypo-fractionation in the setting of a low α/β value of the tumor. Brenner and Hall [7] utilized the
LQ model in combination with the Lea-Catcheside function (a generalization of the LQ model that is useful
at higher doses or prolonged doses) to conclude that due to its slow response to radiation, prostate cancer can
be treated equally effectively by either uniform radiation scheduling or hypo-fractionation (which has fewer
side effects). Unkelbach et al. [34] studied the interdependence between optimal spatial dose distribution
and creation of fractionation schedules. Another work [5] utilized a dynamic programming approach to study
the problem of optimal fractionation schedules in the presence of various repopulation curves. An important
property common to all of these works is that they utilize an objective function that seeks to minimize final
primary tumor population size in some sense. While this can be an important objective, in most cancers,
it is ultimately metastatic disease that proves fatal. Therefore, in this work, we study optimal fractionation
schedules when using an objective function that seeks to minimize the total production of metastatic cells.
The understanding of the metastatic process and how to respond to it has been greatly aided by the
mathematical modeling community (for an overview of this contribution see the recent review paper [30]).
In an interesting work [20], Iwata et al. developed a set of differential equations governing the population
dynamics of the metastatic population. A compelling work is the paper by Thames et al. [32] where they
developed a mathematical model of the metastatic process to calculate risk from metastatic disease due to
delay in surgery. Hanin and Korosteleva [21] used a stochastic model to address questions such as: (1) how
early do metastasis events occur, (2) how does extirpation of the primary affect evolution of the metastasis,
and (3) how long are metastasis latent? Haeno and Michor [16] developed a multitype branching process
model to study metastasis and in particular the probability of metastasis being present at diagnosis. In a
follow up work [15], they used a mathematical model to study metastasis data in recently deceased pancreatic
cancer patients. In a recent work [10], Diego et al. used an ODE model to study the relationship between
primary and metastatic cancer sites, and in particular, makes predictions about the clinical course of the
disease based on the parameter space of their ODE model.
The remainder of the paper is organized as follows. In section 2, we discuss a model for metastasis
production and how it can be used to develop a function that reflects metastatic risk. Next, in section 3, we
describe the optimization model and solution approach. Finally, in section 4, we present numerical results
in the setting of breast cancer.
2 A New Objective Function
We start by assuming that the total population of primary tumor cells at time t is given by the function
Xt. Note we will assume throughout this work that the population of cells is large enough that we can
treat the population as a deterministic function. We then assume that each tumor cell initiates a successful
macrometastasis at rate ν > 0 per unit of time. This is similar to the modeling approach taken in [15] where
they were able to fit their model to metastasis data from patients. If we are interested in the time horizon
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[0, T ] then our total rate of production of successful macrometastasis on that interval is
R1(T ) = ν
∫ T
0
Xtdt.
In particular N(T ), the number of successful metastasis established in the time interval in [0, T ], is a Poisson
random variable with mean R1(T ) and thus the probability of metastasis occurring is P (N(T ) > 0) =
1− exp (−R1(T )). Therefore, in order to minimize P (N(T ) > 0), it suffices to minimize R1(T ).
In the rate R1(T ), we assume that every cell is capable of metastasis. In the geometry of the actual
tumor, it might be the case that only those cells on the surface of the tumor are capable of metastasis, or
only those cells in close proximity to a blood vessel are capable. Therefore, we consider the generalization
Rξ(T ) = ν
∫ T
0
(Xt)
ξ
dt
for 0 < ξ ≤ 1. This is similar to the model of metastasis creation in [20]; there they refer to the parameter
ξ as the fractal dimension of the blood vessels infiltrating the tumor, If we assume that the tumor is three
dimensional with a two dimensional surface and that all cells on the surface are equally capable of metastasis
then we can take ξ = 2/3. However if we assume that only a small fraction of cells on the surface are capable
of metastasis we could take e.g., ξ = 1/3. Notice that in order to minimize Rξ(T ), we do not need to know
the parameter ν, which is difficult to measure.
Note that we are using a rather simplistic model for the metastasis production in that we assume at most
only two rates of metastasis for the primary tumor cells. In reality, it is likely that the rate of metastasis for
a given cell will be a complex function of its position, migratory potential, and its oxidative state. However,
given the lack of data available, we found it preferable to work with this relatively simplistic model that
does not require the knowledge of any intricate parameters. In addition, since the primary goal of this work
is to introduce a novel objective function, we feel that adding further biological details can be saved for
further exploration. Lastly and importantly, variants of this relatively simplistic model have been matched
to clinical metastasis data [15].
3 Optimization Model and Approach
Our goal is to determine an optimal radiotherapy fractionation scheme that minimizes the probability that
the primary tumor volume metastasizes. Given the discussion from the previous section, this equates to
minimizing Rξ(T ); however, for simplicity, we will use an approximate objective that uses a summation
rather than an integral during therapy. Let the time horizon T consists of treatment days and a potentially
long period of no treatment at the end of which metastatic risk is evaluated. Suppose a radiation dose dt is
delivered at time instant t, for t = 1, . . . , N0, then we choose to minimize
N0∑
t=1
(X−t )
ξ +
∫ T
N0
(Xt)
ξ ≈ Rξ(T )/ν
where X−t is the number of cells immediately before the delivery of dose dt.
During the course of the treatment, we assume exponential tumor growth with a time lag. Beyond that,
we use the Gomp-ex model for tumor growth because we are evaluating long-term metastatic risk and the
exponential model will give unreasonably large values over such a long time period. The Gomp-ex law of
growth assumes that the cellular population expands through the exponential law [38] initially, when there
is no competition for resources. However, there is a critical size threshold C such that for X > C the growth
follows the Gompertz Law. Thus, we have
X−t = X0 exp
(
−(αT
t−1∑
i=1
di + βT
t−1∑
i=1
d2i ) +
ln 2
τd
(t− Tk)+
)
, (1)
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for t = 1, . . . , N0 and
Xt =
{
X0 exp
(
−(αT
∑N0
i=1 di + βT
∑N0
i=1 d
2
i ) +
ln 2
τd
(t− Tk)+
)
, Xt ≤ C
K exp
(
log
(
C
K
)
e−δ(t−Tc)
)
, Xt > C
(2)
for t ∈ (N0, T ] where αT and βT are tumor tissue sensitivity parameters, τd is the tumor doubling time
in units of days, Tk is the tumor kick-off time, X0 is the tumor size at the starting of treatment, K is the
carrying capacity and δ is a constant related to the proliferative ability of the cells. The expression (t−Tk)+
is defined as max(0, t− Tk). Tc is the time when the tumor population reaches size C and can be computed
using following equation
Tc =
τd
ln 2
(
ln
(
C
X0
)
+ αT
N0∑
i=1
di + βT
N0∑
i=1
d2i
)
+ Tk.
We also use the concept of biological effective dose (BED) to constrain the side-effects in the OAR around
the tumor. We assume that a dose d results in a homogeneous dose γid in the ith OAR, where γi is the
sparing factor; for the heterogeneous case, it is possible to use the approach in [34]. The BED in the ith
OAR is defined by
BEDi =
N0∑
t=1
γidt
(
1 +
γidt
[α/β]i
)
, (3)
where [α/β]i is an OAR tissue sensitivity parameter. The BED can be derived from the LQ model and is used
to quantify fractionation effects in a clinical setting. Note that we can also have multiple BED constraints
on a single OAR, e.g., to model early and late effects.
The optimization problem of interest is
minimize
dt≥0
(X0)
ξ
N0∑
t=1
exp
(
−ξ
(
αT
t−1∑
i=1
di + βT
t−1∑
i=1
d2i − ln 2
τd
(t− Tk)+
))
+
∫ T
N0
(Xt)
ξ, (4)
s.t.
N0∑
t=1
γidt
(
1 +
γidt
[α/β]i
)
≤ ci, i = 1, . . . ,M
where ci is a constant that specifies an upper bound to the ith BED in the OAR and M is the total number
of OARs in the vicinity of tumor. Note that we do not work directly with the quantity Rξ during therapy
but instead with its approximation Rˆξ =
∑N0
t=1
(
X−t
)ξ. Here, Rˆξ is an upper bound for Rξ and is a good
approximation for Rξ if the impact of the exponential growth term in (1) is relatively small compared to the
dose fraction terms, which is typically the case for most disease sites.
Formulation (4) is a nonconvex quadratically constrained problem. Such problems are computationally
difficult to solve in general. However, we can use a dynamic programming (DP) approach with only two
states to solve this deterministic problem, similar to the work in [5]. The states of the system are Ut, the
cumulative dose, and Vt, the cumulative dose squared, delivered to the tumor immediately after time t. We
have
Ut = Ut−1 + dt
Vt = Vt−1 + d2t
Now we can write the DP algorithm (forward recursion) as
Jt(Ut, Vt) =

mindt≥0[X
ξ
0e
−ξ
(
αT (Ut−1+dt)+βT (Vt−1+d2t )− ln 2τd
(t−Tk)+
)
+ Jt−1(Ut−1, Vt−1)], t ≤ N0 − 1
mindt≥0[X
ξ
0e
−ξ
(
αT (Ut−1+dt)+βT (Vt−1+d2t )− ln 2τd
(t−Tk)+
)
+ Jt−1(Ut−1, Vt−1)] +
∫T
N0
(Xt)
ξ, t = N0
with (U0, V0) = (0, 0), J0(0, 0) = 0. We set the function Jt(Ut, Vt) to be ∞ if
γiUt +
γ2i
[α/β]i
Vt > ci
for any i = 1, . . . ,M . Since there are only two state variables, we can solve our optimization problem by
discretizing the states and using this DP algorithm.
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4 Numerical Results
We solve the optimization problem based on the radiobiological parameters for breast cancer. We consider
two different normal tissues [19], heart and lung tissue. For each normal tissue, we define the maximal
toxicity
ci = γiDi +
γ2i
[α/β]i
D2i
Ni
(5)
whereDi andNi are tissue specific parameters and define the maximum total doseDi delivered inNi fractions
for each OAR. A standard fractionated treatment is to deliver 50 Gy to the tumor with 2 Gy fractions [36].
The tolerance BED values (ci) for various normal tissues were computed based on the standard scheme.
Hence all BED in OAR associated with optimal schedules obtained in this section are less than or equal to
their corresponding BED in standard schedule, i.e. Di = 50 Gy and Ni = 25 for i = 1, 2. All radiobiological
parameter values used are listed in Table 1 along with their sources.
Structure Parameters Values Source
Breast tumor
αT 0.080 Gy−1 [28]
βT 0.028 Gy−2 [28]
τd 14 days [28]
Tk 21 days [33]
X0 0.75× 109 cells [9]
C 4.8× 109 cells [26]
K 3.1× 1012 cells [26]
δ 1.83× 10−3 day−1 [26]
Lung normal tissue
α/β 5 Gy [19]
γ 8.30% [18]
c 4.29 Gy eq. (5)
Heart normal tissue
α/β 3 Gy [19]
γ 2.04% [18]
c 1.03 Gy eq. (5)
Table 1: Breast tumor and normal tissues parameters
For other parameters in our model, unless stated otherwise, we set T = 5 years, ξ = 13 and N0 = 25
days. For numerical implementation of the DP algorithm, we discretize the total dose and dose squared
(Ut, Vt). We used 2500 points to discretize each state variable for every time instant. When evaluating
the cost-to-go function Jt(Ut, Vt) for values in between discretization points, we use bilinear interpolation.
The allowed range for the cumulative dose and cumulative dose squared states are 0 ≤ Ut ≤ mini{ ciγi } and
0 ≤ Vt ≤ mini{ ci[α/β]iγ2i }. For the radiation dose fractions, we allow only multiples of 0.1 Gy. There is a
significant amount of debate, [6, 22], as to whether the linear quadratic model shown in equation (1) applies
to large doses. In view of this, we include a constraint that the dose fractions be no more than 5 Gy.
Figure 1-(a) shows the optimal fractionation schedule when using ξ = 13 . Our model suggests very large
initial doses for the first 9 days followed by a smaller dose on the 10th day if T = 25 days or last day of
treatment otherwise. The results are not surprising because previous works ([25], [3]) have suggested hypo-
fractionation in the case where [α/β]T < mini{[α/β]i/γi}. In order to understand the differences between the
optimal schedules in minimizing metastatic risk T years after the beginning of radiotherapy and minimizing
tumor population at the conclusion of therapy, we consider various settings for model parameters. We report
four of them along with their parameters in Figure 1. We observe that if [α/β]T ≤ mini{[α/β]i/γi} for all
i, then, similar to the case of minimizing tumor population, a hypo-fractionation schedule is still optimal
(case 1 in Figure 1). However if we have [α/β]T > mini{[α/β]i/γi} (cases 2, 3 and 4 in Figure 1), depending
on the model parameters, a hyper-, semi-hyper (a schedule with structure of a large initial dose that tapers
off slowly) or hypo-fractionation schedule is optimal for minimizing metastasis production. Note that in
the last three cases standard schedule (25x2 Gy) with equal doses is optimal when minimizing the tumor
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population at the end of therapy. In addition, we see that for smaller metastatic risk horizon T , with the
same parameters, the optimal schedule tends to be a hypo-fractionation schedule (see the optimal schedule
for case 2, 3 and 4 in Figure 1 when T = 25 days).
Figure 2 explains the logic behind optimal schedules described in Figure 1. The objective function
described in (4) is minimizing ξth root of the area under the tumor size curve, Xt. If there are no clonogenic
cells at the end of the treatment, i.e. full local control, there is no further risk of metastasis after therapy.
In this respect, we need to evaluate the metastasis risk for time interval [0, N0] (T = N0). Thus the optimal
solution is reducing the tumor burden in a very short period of time which supports the optimality of
hypo-fractionated schedules (see blue bars in Figure 1 and Figure 2-A).
However when insufficient dose is delivered to control the primary tumor, the long term metastatic risk
should be considered. In this case our optimization problem minimizes S1 + S2 where S1 is the area under
the tumor size curve in [0, N0] and S2 is the area for (N0, T ]. Therefore the problem of minimizing tumor
burden as quickly as possible (small S1) and maximizing tumor control (which results in small S2) must be
optimized simultaneously. If there is a possibility of metastasis creation for a long period of time, we need to
evaluate metastasis risk for larger values of T , e.g. T = 5 years, where we have S1  S2. Therefore having
minimal number of XN0 is more effective than immediate reduction of the tumor burden. It explains the
optimality of standard schedule in Case 2 and Case 4 of Figure 1 when we set T = 5 years (note that in
these three cases we have [α/β]T > mini{[α/β]i/γi} where an equal dosage regime minimizes XN0).
Finally we explore an interesting property of the optimal schedules in Figure 1. When we evaluate the
long term metastatic risk, if the hypo-fractionated schedule is optimal, we observe that it is preferable to
deliver the last dose of radiation on the last day of treatment (see Case 1 and Case 2 in Figure 1). When
Tk < N0 and we are unable to fully control the primary tumor, then clonogenic cells start to repopulate
during the course of treatment. On the other hand if we deliver the last dose on the last day, a larger
population of clonogenic cells are affected which results in smaller XN0 and an improvement in the objective
function in long term (compare the solid and dashed blue curves in Figure 2-B). Note that this result depends
on some values of model parameters, e.g. tumor growth rate, tumor kick-off time and etc, and may not hold
for a different tumor with distinct parameters.
We perform an extensive sensitivity analysis of the optimal solution with respect to model parameters
(ξ, N0, τd, Tk and δ). We see that after including different parameters the minimization of metastasis risk
is still achieved by a hypo-fractionated schedule presented in Figure 1-(a). In addition, we see that for
smaller T radiation is concentrated at the beginning of the schedule. Figure 3 plots the optimal values of the
objective function in (4) for different values of model parameters. The structure of the optimal fractionation
is relatively robust to model parameters; the only parameters that change this structure are T , [α/β]i, [α/β]T
and γi (See Figure 1).
We consider the relative effectiveness of an optimized schedule versus a standard schedule (delivering
50 Gy to the tumor with 2 Gy fractions in 5 weeks [36]). In particular, if we denote the approximate
metastasis risk under the optimized schedule by νRˆoptξ , and the risk under a standard uniform fractionation
by νRˆstdξ . Then, the ratio re = (Rˆ
std
ξ − Rˆoptξ )/Rˆstdξ will give us a measure of the predicted relative reduction
in metastasis risk associated with using the optimized schedule instead of the standard schedule. These
results are presented in Table 2. In the case of eradicating the primary tumor, we should only consider
the metastasis production during the course of treatment (T = 0.07). In this case, we see a significant
reduction in metastasis risk for all values of [α/β]T studied. However if insufficient dose is delivered to the
tumor, primary tumor begins to repopulate after therapy and we require to choose a bigger T to evaluate the
metastasis risk since cancer metastasizes either during or after treatment (T = 1, 2, 3, 4, 5 years). In general
we see that the risk reduction decreases with [α/β]T and the evaluation period, but optimal schedule still
provides for a substantial risk reduction for all values of [α/β]T and T studied.
5 Conclusion
In this work, we have considered the classic problem of optimal fractionation schedules in the delivery
of radiation. We have however done this with the non-traditional goal of minimizing the production of
metastasis. This is motivated by the fact that the majority of cancer fatalities are driven by metastasis [14,
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(a) Case 1 (b) Case 2
(c) Case 3 (d) Case 4
Figure 1: Optimal fractionation schedule with evaluating objective function immediately after treatment,
1 and 5 years after conclusion of therapy. (a) This plot shows that if [α/β]T ≤ mini{[α/β]i/γi} then
a hypo-fractionated schedules minimize both tumor cell population at the conclusion of treatment and
metastasis risk. In this case we have [α/β]T = 2.86 and mini{[α/β]i/γi} = 60.24. (b)-(d) In these three
cases we have [α/β]T > mini{[α/β]i/γi} where an equal-dosage routine minimizes the number of tumor
cells at the conclusion of therapy. However we observe that hypo-fractionated schedules are still the best
choices when minimizing metastatic risk in short term (see blue and red bars above). Evaluating metastatic
risk in long term, optimal schedules change to an equal-dosage routine (gray bars in case 2 and case 4)
or a semi-hyper-fractionated schedule (gray bars in case 3), which shows the sensitivity of these structure
with respect to T , α, β and OAR parameters. In cases b, c and d, we have [α/β]T = 64.26, 16, 8 and
mini{[α/β]i/γi} = 60.24, 15.7, 7.5, respectively.
[α/β]T
5 6 7 8 9 10 11 12 13 14 15
T = 0.07 53.16% 48.97% 45.55% 42.74% 40.39% 38.40% 36.70% 35.23% 33.95% 32.82% 31.81%
T = 1 20.93% 17.10% 14.39% 12.37% 10.82% 9.58% 8.57% 7.73% 7.02% 6.42% 5.89%
T = 2 10.72% 8.76% 7.37% 6.33% 5.52% 4.87% 4.35% 3.91% 3.54% 3.22% 2.95%
T = 3 6.94% 5.66% 4.76% 4.08% 3.55% 3.13% 2.79% 2.51% 2.27% 2.06% 1.89%
T = 4 4.88% 3.98% 3.34% 2.86% 2.49% 2.2% 1.96% 1.76% 1.59% 1.45% 1.32%
T = 5 3.63% 2.96% 2.49% 2.13% 1.86% 1.64% 1.46% 1.31% 1.18% 1.08% 0.98%
Table 2: Metastasis risk reduction of optimized schedule evaluated T years after therapy.
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Figure 2: Optimality of standard and hypo-fractionated schedules when A) there are no clonogenic cells at
the end of treatment, i.e. full local control. In this case, reducing the tumor size in a short period of time
is the optimal strategy. B) insufficient dose is delivered to control the primary tumor and the long term
metastatic risk should be considered. In this case in addition to reducing the tumor size at the beginning
of the therapy, having small number of clonogenic cells on the last day of treatment is also important. The
area under the solid and dashed blue curves explains the property of delivering the last dose on the last day
instead of 10th and 15th day in Case 1 and Case 2 of Figure 1, respectively.
37], and that this disseminated disease can be very difficult to treat. We addressed this goal by considering
the optimal fractionation problem with a novel objective function based on minimizing the total rate of
metastasis production, which we argue is equivalent to minimizing the time integrated tumor cell population.
We were able to numerically solve this optimization problem with a dynamic programming approach.
We computed radiotherapy fractionation schedules that minimized metastatic risk for a variety of pa-
rameter settings. The resulting optimal schedules had an interesting structure that was quite different from
what is observed from the traditional optimal fractionation problem where one is interested in minimiz-
ing local tumor population at the end of treatment. In the traditional optimal fractionation problem it
was observed in [29] that if [α/β]T ≤ mini{[α/β]i/γi} then a hypo-fractionated schedule is optimal and if
[α/β]T > mini{[α/β]i/γi} then a hyper-fractionated schedule is optimal. In contrast, in the current work
we observed that if we are evaluating metastatic risk at the conclusion of therapy then independent of
the relationship between [α/β]T and mini{[α/β]i/γi}, the resulting fractionation schedules for minimizing
metastatic risk is a hypo-fractionated structure with large initial doses that taper off quickly. This is due
to the structure of the objective function. In order to minimize the time integrated tumor cell population
immediately after treatment, it is necessary to quickly reduce the tumor cell population since this is the high
point of the tumor cell population over the course of the treatment. If we think of the tumor cell population
as quite dangerous due to its metastasis potential, then it is natural to want to reduce their population as
quickly as possible.
We observed that the structure of the optimal schedule depends on the length of time for which we
evaluated metastatic risk. In particular if we evaluate metastasis risk in a long time frame (several years)
after therapy, and it holds that [α/β]T > mini{[α/β]i/γi}, then the optimal schedule will have either medium
initial doses tapering off slowly (that is, a schedule where d1 ≥ d2 ≥ · · · ≥ dN0) or equal-dosage routine
where we have d1 = d2 = · · · = dN0 . This is in contrast to when we evaluate metastatic risk over the course
of the treatment period, in which case a hypo-fractionated schedule is nearly always optimal. Note that if
our evaluation time-frame of metastatic risk is several years after the conclusion of therapy, then we want to
minimize the tumor cell population as soon as possible to reduce initial metastatic risk, but we also need to
avoid a large tumor population in the long time period after the conclusion of treatment.
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(a) Sensitivity analysis w.r.t ξ (b) Sensitivity analysis w.r.t N0, τd, Tk and δ
Figure 3: a) This plot shows the sensitivity of number of metastasis produced by tumor with respect to
ξ. The structure of the optimal schedule is robust to variation in ξ, however the metastasis production is
affected dramatically by this parameter. b) This plot shows the sensitivity of metastasis production with
respect to N0, τd, Tk and δ. The optimal schedules associated with various values of these parameters are
the same as the optimal schedule obtained in Figure 1-(a). The effects of treatment duration and tumor
kick-off time are negligible in the model’s output; however, the exponential and Gompertz growth rate can
change the optimal value.
In many of our results, we observed the optimality of hypo-fractionated schedules. Interestingly, previous
clinical trials, e.g., the FAST trial for breast cancer [39] and the CHHIP trial for prostate cancer [40],
show the benefit of hypo-fractionation. It should be noted that the motivation for these trials was the low
[α/β]T value in prostate and breast tumors. Our results indicate even when the [α/β]T ratio of the tumor
is very large, it may still better to deliver a hypo-fractionated schedule when taking metastatic risk into
account. The current work provides a possible new motivation for considering hypo-fractionated schedules,
i.e., metastasis risk reduction.
In this paper, we have assumed the delivery of single daily fractions and have not considered alternate
fractionation schemes such as CHART [17] that deliver multiple fractions a day. Some of our results indicate
optimal hypo-fractionation schedules (as obtained for the T=0.07 case). One way to deliver a large amount
of dose in a very short period of time is to use such schemes like CHART. However, additional modeling is
needed to incorporate incomplete sublethal damage repair due to short inter-fraction time periods.
Another possible interpretation of this work is to view the output Rξ as the risk of the tumor developing
resistance to a chemotherapeutic treatment. This can be achieved by simply viewing the parameter ν as the
rate at which tumor cells develop drug resistance. Due to the severe consequences of drug resistance, this is
also an interesting direction for further exploration.
We feel that this type of work minimizing metastatic production opens the potential for a new line of
research in the radiation optimization community as well as cancer biology. In particular, there are several
important biological phenomena that we have not included. This includes oxygenation status (and history)
of cells as well as the vascular structure of the tumor of interest. Lastly, a potentially interesting extension
of this work could be to validate our predictions in animal models of metastatic cancer.
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